Alto Neuroscience (ANRO) Non-Current Debt (2023 - 2026)

Alto Neuroscience has reported Non-Current Debt for 4 years, with the latest figure at $13.9 million in Q1 2026.

• Quarterly Non-Current Debt fell 30.37% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (down 30.37% YoY) and the FY2025 annual result came in at $16.2 million, up 57.71% from the prior year.
• Non-Current Debt eased to $13.9 million in Q1 2026 per ANRO's latest filing, from $16.2 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $20.3 million in Q3 2025 and troughed at $9.9 million in Q4 2023.
• A 4-year average of $14.1 million and a median of $12.1 million in 2024 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt soared 100.22% in 2025, then tumbled 30.37% in 2026.
• Over 4 years, Non-Current Debt stood at $9.9 million in 2023, then increased by 3.99% to $10.3 million in 2024, then surged by 57.71% to $16.2 million in 2025, then decreased by 14.14% to $13.9 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $13.9 million, $16.2 million, and $20.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.